Navigation Links
Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
Date:6/30/2009

ave sufficient financial resources to support the additional contemplated later-stage trials. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                  Media
    info@peregrineinc.com                      Barbara Lindheim
    (800) 987-8256                             (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... geared to patients and family members, medical professionals, and researchers, covering a variety ... The conference is a collaborative effort between the Mesothelioma Applied Research Foundation and ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, hosted by ... and 6. The event attracts over 250 “C”-level executives, administrators, directors of ...
(Date:7/31/2015)... ... 31, 2015 , ... The Mount Sinai Health System will work with Columbia ... of related, experimental treatments. The collaboration moves into the next phase with the recent ... of five state licenses to produce and dispense medical marijuana. , Mount Sinai ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... penile enlargement techniques have also been advanced, upgraded, made more effective and less intrusive ... Loria of Loria Medical Penile Enlargement Center. Dr. Loria currently stands as the ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has ... angina until a heart rate of 150 beats versus 100 beats, this is a ... are able to give life back to patients with heart disease," he adds. People ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... who reported sleeping five hours or less per day when ... risk for substantial weight retention (11 pounds or more) at ... per day, according to a new study by Kaiser Permanente ... , The study, published in the November issue of ...
... Optimal Nutrition Inc. Chooses ,it, Girl PR to help promote ... ... 19 "it" Girl Public relations, one of,the leading Public ... addition of Optimal Nutrition Inc. (O.N.I.).,O.N.I. bestows a customized door-to-door ...
... Agency ... in Massachusetts -, WORCESTER, Mass., Nov. 19 The ... of auto, home and,business insurance in Massachusetts, announced today that ... auto product that will,deliver highly- competitive prices and innovative coverage ...
... Calif., Nov. 19 CorVel Corporation,(Nasdaq: CRVL ... shares,of its common stock under the stock repurchase ... In June 2006, the Board had approved a,1,500,000 ... 30,2007, the Company has repurchased 862,323 shares, with ...
... made, MINNEAPOLIS, Nov. 19 At its ... Directors of ClearWay Minnesota approved 11,grants for new ... Breathe Act,s,impact on young adults to interventions that ... Latino youth and African,immigrants. ClearWay Minnesota will award ...
... U.N. Environment Initiative to Northern New,Jersey, Planting ... MORRISTOWN, N.J., Nov. 18, 2007 Reaffirming,its ... Bayer,employee-volunteers and Girl Scouts from troops in ... grabbed their spades and planted 10,trees at ...
Cached Medicine News:Health News:Kaiser Permanente/Harvard Medical School study links lack of sleep to weight gain for new moms 2Health News:'it' Girl Public Relations Adds 'O.N.I.' New Organic Food Delivery Service to Its Lifestyle Division 2Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 2Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 3Health News:The Hanover Seeks to Cut Auto Rates by Up to 30 Percent or More; Shave Three Years Off State's Existing Six-Year Surcharge Period 4Health News:CorVel Corporation Announces Resumption of Stock Repurchases 2Health News:CorVel Corporation Announces Resumption of Stock Repurchases 3Health News:ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants 2Health News:ClearWay Minnesota(SM) Board Approves $2.8 Million for Research Grants 3Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 2Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 3Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 4Health News:Bayer Awards Making Science Make Sense Grant to Girl Scouts 5
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a ... extracellular matrix, today announced,that enrollment is complete in ... of superficial bladder cancer. The Company began dosing,patients ... following the successful,completion of the initial Phase I ...
... Pharmacopeia,(Nasdaq: PCOP ), an innovator in ... today announced that Schering-Plough has,initiated a Phase 1 ... a,compound identified from the collaboration between the two ... treatment for respiratory,disease. Pharmacopeia will receive a $1 ...
Cached Medicine Technology:Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer 2Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer 3Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer 4Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 2Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 3Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 4
The New Digital Recording System From Luxtec,The new MicroLux Digital Video Recorder gives you an entirely new way to visualize, edit, share and store your surgical cases....
... sensor array with 275 channels ... of just 2.2 cm. This ... useful when using advanced analysis ... Magnetometry (SAM) or minimum norm ...
... , with its large array of 148 ... the localization of activity throughout the entire ... millimeter spatial resolution. Featuring an operator interface ... rapid data processing and display, the Magnes ...
... CXDI-50G is a one-of-kind portable Digital Radiography system ... bedside exams.,It has a 14 x 17- inch ... ,With a large imaging area and lightweight ... possible with Digital Radiography. It is large enough ...
Medicine Products: